抗CD200抗体靶向治疗儿童白血病增殖细胞
儿童急性淋巴细胞白血病(ALL)虽缓解率超90%,但缺乏CD19的白血病增殖细胞(LPC)可致复发。研究分析CD58、CD97和CD200在LPC亚群中的表达,发现CD200对MRD低危患者细胞植入和连续移植必需,单克隆抗体TTI-CD200可在体内外靶向CD200+ LPC,减轻疾病负荷并延长生存。
要点
- CD200在MRD低危ALL的LPC中高表达且为植入所必需。
- TTI-CD200抗体可体外和体内靶向CD200+ LPC。
- 治疗小鼠可显著减轻疾病负荷并延长生存。
核心结论
- CD200是治疗低危ALL的潜在靶点,可靶向缺乏CD19的LPC且脱靶效应小。
研究设计与样本
- 研究分析CD58、CD97和CD200在CD34+/CD19+、CD34+/CD19-、CD34-/CD19+和CD34-/CD19- LPC亚群中的表达。
- 采用全基因组微阵列和流式细胞术分析,并在免疫缺陷小鼠中进行植入和连续移植实验。
- 体外和体内评估单克隆抗体TTI-CD200对CD200+ LPC的靶向作用。
主要发现
- CD58、CD97和CD200在B细胞前体ALL中较正常对照显著过表达。
- CD58和CD97主要与CD19共表达,且不是白血病植入的先决条件。
- CD200表达对MRD低危患者细胞的植入和连续移植必需。
- TTI-CD200在体外和体内可靶向CD200+ LPC。
- 治疗患病小鼠可显著减轻疾病负荷并延长生存。
临床怎么用
- CD200可作为低危ALL的免疫治疗靶点,尤其针对缺乏CD19的LPC。
- TTI-CD200抗体可能减少脱靶效应,但需进一步临床验证。
局限性
- 研究主要基于临床前模型,尚未在患者中验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treating refractory pediatric acute lymphoblastic leukemia (ALL) remains a challenge despite impressive remission rates (>90%) achieved in the last decade. The use of innovative immunotherapeutic approaches such as anti-CD19 chimeric antigen receptor T cells does not ensure durable remissions, because leukemia-propagating cells (LPCs) that lack expression of CD19 can cause relapse, which signifies the need to identify new markers of ALL. Here we investigated expression of CD58, CD97, and CD200, which were previously shown to be overexpressed in B-cell precursor ALL (BCP-ALL) in CD34+/CD19+, CD34+/CD19-, CD34-/CD19+, and CD34-/CD19- LPCs, to assess their potential as therapeutic targets. Whole-genome microarray and flow cytometric analyses showed significant overexpression of these molecules compared with normal controls. CD58 and CD97 were mainly co-expressed with CD19 and were not a prerequisite for leukemia engraftment in immune deficient mice. In contrast, expression of CD200 was essential for engraftment and serial transplantation of cells in measurable residual disease (MRD) low-risk patients. Moreover, these CD200+ LPCs could be targeted by using the monoclonal antibody TTI-CD200 in vitro and in vivo. Treating mice with established disease significantly reduced disease burden and extended survival. These findings demonstrate that CD200 could be an attractive target for treating low-risk ALL, with minimal off-tumor effects that beset current immunotherapeutic approaches.
引用
- Diamanti P, Cox CV, Ede BC, et al. Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy. Blood Adv. 2021. PMID: 34470052. doi:10.1182/bloodadvances.2020003534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。